Trump prescription medication plan drawing skepticism image

Boston Herald, November 3, 2018
Alexi Cohan, quoting Rachel Sachs (Academic Fellow Alumna)


Read the Full Article

From the article:

Part of the proposal includes adopting an international pricing index for reimbursement that is based off the cost of certain drugs in other countries. This would lower the cost here in the United States, which can drop out-of-pocket expenses for patients. However Rachel Sachs, an associate professor of law at the Washington University School of Law in Missouri, said our foreign neighbors may be reluctant to lend a hand.

“This proposal is in some sense free-riding on the efforts of other countries who have made hard decisions about drug pricing and reimbursement,” said Sachs. “Why would other countries let us do that?”

Sachs said she expects interest groups to come out and fight the proposal, including the pharmaceutical industry, oncology and physicians groups, and patient groups. Sager echoed this sentiment, saying drug companies will “fight it to the death” in fear the plan could set a precedent for the future, causing the companies to lose money.

Read more here!

health care reform health law policy pharmaceuticals rachel sachs